First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded enrollment No significant safety or dose limiting toxicities have been...Read more
DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr....Read more
Preclinical data demonstrates that SPY003 is highly potent and has potential for quarterly or biannual dosing, suggesting opportunity for improved efficacy and convenience over first-generation anti-IL-23 monoclonal antibodies Interim pharmacokinetic and safety...Read more
U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...Read more
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical...Read more
Priority Review Was Requested, Commercial Launch Preparations Underway MOLBREEVI Has the Potential to Be the First and Only Approved Therapy for aPAP in the U.S. and Europe Company Remains on Track to Submit the Marketing Authorization Application (MAA) in Europe by the End of...Read more
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Soleno Therapeutics | 18.42 37.61 | $67.39 |
| argenx | 9.81 1.68 | $593.47 |
| Alcon | 5.48 6.00 | $96.80 |
| HCA Healthcare | 5.05 1.50 | $342.34 |
| IDEXX Laboratories | 4.83 1.16 | $422.54 |
| Abbott | 4.74 3.74 | $131.35 |
| Madrigal Pharmaceuticals | 4.18 1.25 | $338.00 |
| Cigna | 3.51 1.09 | $324.74 |
| Monopar Therapeutics | 3.29 8.64 | $41.39 |
| Chemed | 3.19 0.52 | $612.36 |
| Waters | 2.80 0.76 | $370.59 |
| Cardinal Health | 2.67 1.99 | $136.65 |
| McKesson | 2.65 0.40 | $665.67 |
| Axsome Therapeutics | 2.61 2.19 | $121.77 |
| Ascendis Pharma | 2.40 1.52 | $160.68 |
| RxSight | 2.30 9.44 | $26.67 |
| Mettler-Toledo | 2.30 0.19 | $1,193.33 |
| Vertex Pharmaceuticals | 2.27 0.45 | $502.55 |
| Company | Volume | Last Trade |
|---|---|---|
| Ocean Biomedical | 214,708,215 | $0.07 |
| 23andMe | 178,523,504 | $0.75 |
| Dermata Therapeutics | 75,745,235 | $1.40 |
| Onconetix | 68,571,767 | $0.11 |
| Petros Pharmaceuticals | 58,236,752 | $0.11 |
| Pfizer | 48,640,202 | $25.02 |
| Tenon Medical | 41,141,019 | $2.77 |
| Regulus Therapeutics | 32,277,767 | $1.47 |
| Nkarta | 27,116,522 | $1.94 |
| ImmunityBio | 16,315,928 | $3.33 |
| Brookdale Senior Living | 16,287,647 | $5.91 |
| Plus Therapeutics | 15,268,167 | $1.52 |
| Soleno Therapeutics | 15,149,029 | $67.39 |
| Recursion | 14,286,878 | $5.98 |
| Geron | 12,048,017 | $1.66 |
| Viatris | 11,667,138 | $8.84 |
| PacBio | 11,046,156 | $1.30 |
| Merck | 10,930,626 | $87.60 |
| Walgreens Boots Alliance | 9,859,920 | $11.16 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
